ホーム>>Signaling Pathways>> Immunology/Inflammation>> Adaptive Immunity>>(E)-C-HDMAPP (ammonium salt)

(E)-C-HDMAPP (ammonium salt) (Synonyms: (E)5hydroxy4methylpent3enyl pyrophosphate)

カタログ番号GC41703

合成および天然のアルキルホスフェート、またはフォスホアンチゲンとしても知られる物質は、γδ-Tリンパ球の増殖を刺激します。

Products are for research use only. Not for human use. We do not sell to patients.

(E)-C-HDMAPP (ammonium salt) 化学構造

Cas No.: 933030-60-5

サイズ 価格 在庫数 個数
500μg
$104.00
在庫あり
1mg
$199.00
在庫あり
5mg
$836.00
在庫あり
10mg
$1,463.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Synthetic and natural alkyl phosphates, also known as phosphoantigens, stimulate the proliferation of γδ-T lymphocytes. Isopentenyl pyrophosphate, and related derivatives including (E)-hydroxy-dimethyl-allyl pyrophosphate ((E)-HDMAPP), are particularly effective activators of γδ-T cells. (E)-C-HDMAPP is the pyrophosphonate form of (E)-HDMAPP. The pyrophosphonate moiety in (E)-C-HDMAPP is much less susceptible to chemical or enzymatic hydrolysis than its pyrophosphate counterpart. As a result, (E)-C-HDMAPP is much more stable in solution and in vascular circulation. (E)-C-HDMAPP possesses comparable activity to (E)-HDMAPP, which is the most potent of the isoprenoid phosphoantigens. (E)-C-HDMAPP stimulates the synthesis of tumor necrosis factor (TNF-α) by γδ-T lymphocytes with an IC50 value of 0.91 nM. (E)-C-HDMAPP also significantly increases the number of circulating γδ-T cells in vivo, in cynomolgus monkeys.

レビュー

Review for (E)-C-HDMAPP (ammonium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (E)-C-HDMAPP (ammonium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.